Literature DB >> 26077390

Measurement and comparison of health utility assessments in chronic rhinosinusitis.

Elisabeth H Ference1, Vanessa Stubbs2, Alcina K Lidder3, Rakesh K Chandra4, David Conley1, Pedro C Avila5, Annemarie G Hirsch6, Jin-Young Min1, Stephanie Shintani Smith1,7, Robert C Kern1, Bruce K Tan1.   

Abstract

BACKGROUND: Chronic rhinosinusitis (CRS) is a common condition encountered in primary care medicine and is estimated to affect 12.5% of the United States population. This study aims to compare methods of assessing health utility in CRS.
METHODS: A cross-sectional sample of CRS patients (n = 137) were interviewed using direct health utility assessment measures: the visual analogue scale (VAS), time trade-off (TTO), and standard gamble (SG). General quality of life (QOL) scores were obtained via the 36-item Short Form Health Survey (SF-36) and converted to SF-6D health utility values using a Bayesian algorithm. Disease-specific QOL was measured with the 22-item Sino-Nasal Outcome Test (SNOT-22). A selected subgroup of patients (n = 51) not initiating surgery or new treatment for CRS were re-interviewed within 3 weeks.
RESULTS: The mean ± SD health utilities were VAS 0.69 ± 0.19; TTO 0.80 ± 0.27; SG 0.93 ± 0.11; and SF-6D 0.72 ± 0.12; they differed significantly (p < 0.001). Only VAS scores differed based on disease state classification or the presence of nasal polyposis. Correlations between methods of determining health utility were weak, but significant. VAS, TTO, and SF-6D scores were significantly associated with SNOT-22 (p < 0.001 for all); however, SG and SNOT-22 were poorly correlated (Spearman correlation = -0.33). The test-retest reliability of TTO (Spearman correlation = 0.71) and SG (0.73) was strong.
CONCLUSION: CRS patients show significant impairment in QOL, with health utility values similar to those of patients with acquired immune deficiency syndrome (AIDS) or intermittent claudication using similar methods. The method of ascertainment significantly affects measured health utility, but the degree of impairment warrants improved recognition and appropriate treatment of the condition.
© 2015 ARS-AAOA, LLC.

Entities:  

Keywords:  SF-6D; chronic rhinosinusitis; quality of life; standard gamble; time trade-off; utility values; visual analog scale

Mesh:

Year:  2015        PMID: 26077390      PMCID: PMC4607564          DOI: 10.1002/alr.21556

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  37 in total

1.  Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals.

Authors:  Takeshi Morimoto; Tsuguya Fukui
Journal:  J Epidemiol       Date:  2002-03       Impact factor: 3.211

2.  Health utility measures and the standard gamble.

Authors:  Alex G Garza; Kathleen W Wyrwich
Journal:  Acad Emerg Med       Date:  2003-04       Impact factor: 3.451

3.  Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index.

Authors:  Nan Luo; Jeffrey A Johnson; James W Shaw; David Feeny; Stephen Joel Coons
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

4.  Can the standard gamble and rating scale be used to measure quality of life in rhinoconjunctivitis? Comparison with the RQLQ and SF-36.

Authors:  E F Juniper; A K Thompson; J N Roberts
Journal:  Allergy       Date:  2002-03       Impact factor: 13.146

5.  A utility maximization model for evaluation of health care programs.

Authors:  G W Torrance; W H Thomas; D L Sackett
Journal:  Health Serv Res       Date:  1972       Impact factor: 3.402

Review 6.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

7.  Psychometric validity of the 22-item Sinonasal Outcome Test.

Authors:  C Hopkins; S Gillett; R Slack; V J Lund; J P Browne
Journal:  Clin Otolaryngol       Date:  2009-10       Impact factor: 2.597

8.  Quality of life in Taiwanese adults with chronic rhino-sinusitis.

Authors:  Pa-Chun Wang; Chih-Jaan Tai; Min-Shung Lin; Chia-Chen Chu; Shu-Cheng Liang
Journal:  Qual Life Res       Date:  2003-06       Impact factor: 4.147

9.  The health impact of chronic sinusitis in patients seeking otolaryngologic care.

Authors:  R E Gliklich; R Metson
Journal:  Otolaryngol Head Neck Surg       Date:  1995-07       Impact factor: 5.591

Review 10.  Health-related quality of life in patients with sinusitis.

Authors:  Jeffrey A Linder; Steven J Atlas
Journal:  Curr Allergy Asthma Rep       Date:  2004-11       Impact factor: 4.919

View more
  10 in total

1.  Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitis.

Authors:  Griet A Van Roey; Christopher C Vanison; Jeffanie Wu; Julia H Huang; Lydia A Suh; Roderick G Carter; James E Norton; Stephanie Shintani-Smith; David B Conley; Kevin C Welch; Anju T Peters; Leslie C Grammer; Kathleen E Harris; Kathryn E Hulse; Atsushi Kato; Whitney W Stevens; Robert C Kern; Robert P Schleimer; Bruce K Tan
Journal:  J Allergy Clin Immunol       Date:  2016-12-12       Impact factor: 10.793

2.  Evidence for altered levels of IgD in the nasal airway mucosa of patients with chronic rhinosinusitis.

Authors:  Jin-Young Min; Jayakar V Nayak; Kathryn E Hulse; Whitney W Stevens; Paul A Raju; Julia H Huang; Lydia A Suh; Griet A Van Roey; James E Norton; Roderick G Carter; Caroline P E Price; Ava R Weibman; Ali R Rashan; Eliver E Ghosn; Zara M Patel; Tetsuya Homma; David B Conley; Kevin C Welch; Stephanie Shintani-Smith; Anju T Peters; Leslie C Grammer; Kathleen E Harris; Atsushi Kato; Peter H Hwang; Robert C Kern; Leonore A Herzenberg; Robert P Schleimer; Bruce K Tan
Journal:  J Allergy Clin Immunol       Date:  2017-06-16       Impact factor: 10.793

3.  Health utility values for patients with recurrent acute rhinosinusitis undergoing endoscopic sinus surgery: a nested case control study.

Authors:  Toby O Steele; Jess C Mace; Raj Dedhia; Luke Rudmik; Timothy L Smith; Jeremiah A Alt
Journal:  Int Forum Allergy Rhinol       Date:  2016-06-16       Impact factor: 3.858

4.  How often is sinus surgery performed for chronic rhinosinusitis with versus without nasal polyps?

Authors:  Elisabeth H Ference; Jeffrey D Suh; Bruce K Tan; Stephanie Shintani Smith
Journal:  Am J Rhinol Allergy       Date:  2018-01-01       Impact factor: 2.467

Review 5.  Contemporary Pharmacotherapy for Allergic Rhinitis and Chronic Rhinosinusitis.

Authors:  Saied Ghadersohi; Bruce K Tan
Journal:  Otolaryngol Clin North Am       Date:  2017-09-28       Impact factor: 3.346

Review 6.  Targetable pathogenic mechanisms in nasal polyposis.

Authors:  Alexander L Schneider; Robert P Schleimer; Bruce K Tan
Journal:  Int Forum Allergy Rhinol       Date:  2021-03-03       Impact factor: 5.426

7.  Exhalation delivery system with fluticasone improves quality of life and health status: pooled analysis of phase 3 trials NAVIGATE I and II.

Authors:  Zachary M Soler; Sam Colman; Fulton F Velez; Rodney J Schlosser
Journal:  Int Forum Allergy Rhinol       Date:  2020-05-22       Impact factor: 3.858

8.  Radiographic disease severity in chronic rhinosinusitis patients and health care utilization.

Authors:  Mitesh P Mehta; Kevin Hur; Caroline P E Price; Stephanie Shintani-Smith; Kevin C Welch; David B Conley; Robert C Kern; Bruce K Tan
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-09-18

9.  Risk Model Establishment of Endoscopic Sinus Surgery for Patients with Chronic Rhinosinusitis: a Multicenter Study in Korea.

Authors:  Jin-Young Min; Yong Min Kim; Dae Woo Kim; Jeong-Whun Kim; Jin Kook Kim; Ji-Hun Mo; Jae-Min Shin; Kyu-Sup Cho; Sanggyu Kwak; Seung-Heon Shin
Journal:  J Korean Med Sci       Date:  2021-10-18       Impact factor: 2.153

10.  Impact of COVID-19 versus chronic rhinosinusitis/rhinitis associated olfactory dysfunction on health utility and quality of life.

Authors:  Thanh Luong; Sophie S Jang; Mena Said; Adam S DeConde; Carol H Yan
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-09-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.